Randomised trial of coronary intervention with antibody against platelet IIb/IIIa iritegrin for reduction of clinical restenosis: results at six months

The Lancet

Volumn 343, Issue 8902, 1994, Pages 881-886

  Topol, EricJ ^a   Califf, RobertM ^a   Weisman, HarlanF ^a   Ellis, StephenG ^a   Tcheng, JamesE ^a   Worley, Seth ^a   Ivanhoe, Russell ^a   George, BarryS ^a   Fintel, Dan ^a   Weston, Mark ^a   Sigmon, Kristina ^a   Anderson, KeavenM ^a   Lee, KerryL ^a   Willerson, JamesT ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; HEPARIN; IMMUNOGLOBULIN F(AB) FRAGMENT; MONOCLONAL ANTIBODY; PLACEBO;

ARTICLE; BLEEDING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DILATATION; CORONARY ARTERY OBSTRUCTION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR;

EID: 0028345255     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(94)90007-8     Document Type: Article

References (33)

1. Clinical trials of restenosis after coronary angioplasty
2. Analysis of coronary angioplasty practice in the United States using a private insurance database
3. Restenosis: the clinical issues
4. Pharmacological approaches to the prevention of restenosis following angioplasty
5. A paradigm for retenosis based on cell biology: clues for the development of new preventive therapies
6. The role of platelets thrombin and hyperplasia in restenosis after coronary angioplasty
7. Migration of smooth muscle and endothelial cells: critical events in restenosis
8. Evaluation of ketanserin in the prevention of restenosis after percutaneous transluminal coronary angioplasty
9. Does the new angiotensin converting enzyme inhibitor cilazapril prevent restenosis after percutaneous transluminal coronary angioplasty?
10. Cellular adhesion: GPIIb/IIIa as a prototypic adhesion receptor
11. A new murine monoclonal antibody reports an activation-dependent change in the conformation and/or microenvironment of the platelet GP IIb/IIIa complex
12. Safety and antiplatelet effect of murine monoclonal antibody 7E3 Fab directed against platelet glycoprotein IIb/IIIa in patients undergoing elective coronary angioplasty
13. Chimeric antiplatelet GPIIb/IIIa receptor antibody (c7E3) in elective PTCA: safety and platelet function inhibition
14. Prevention of ischemic complications in high-risk angioplasty by a chimeric monoclonal antibody c7E3 Fab fragment directed against the platelet glycoprotein IIb/IIIa receptor
15. Guidelines for percutaneous transluminal coronary angioplasty a report of the American College of Cardiology/American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures (Subcommittee on Percutaneous Transluminal Coronary Angioplasty)
16. Consequences of occlusion during PTCA: the 1985-86 NHLBI PTCA Registry
17. Abrupt vessel closure complicating coronary angioplasty: clinical, angiographic and therapeutic profile
18. Acute coronary artery occlusion during and after percutaneous transluminal coronary angioplasty
19. Nonparametric estimation from incomplete observations
20. Integrins: versatility, modulation, and signaling in cell adhesion
21. Outcome of patients treated with the GPIIb/IIIa inhibitor integrelin during coronary angioplasty: results of the IMPACT study
22. Inhibition of platelet aggregation with a sustained infusion of MK-383 in stable coronary artery disease
23. A comparison of coronary angioplasty with directional atherectomy in patients with coronary artery disease
24. A comparison of directional atherectomy with balloon angioplasty for lesions of the left anterior descending coronary artery
25. 2-receptor blockade: a randomized, double-blind, placebo-controlled trial
26. Sustained inhibition of the vessel wall-platelet interaction after deep coronary artery injury by temporary inhibition of the platelet glycoprotein IIb/IIIa receptor
27. Development of nonthrombogenicity of injured rabbit aortas despite inhibition of platelet adherence
28. Platelet accumulation in experimental angioplasty: time course and relation to vascular injury
29. Studies of activated GPIIb/ IIIa receptors on the luminal surface of adherent platelets
30. The restenosis paradigm revisited: an alternative proposal for cellular mechanisms
31. The restenosis "antitheory"
32. Frequency and severity of cyclic flow alternations and platelet aggregation predict the severity of neointimal proliferation following experimental coronary stenosis and endothelial injury
33. Aspirin and dipyridamole in the prevention of restenosis after percutaneous transluminal coronary angioplasty